ZA202304536B - Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease - Google Patents
Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's diseaseInfo
- Publication number
- ZA202304536B ZA202304536B ZA2023/04536A ZA202304536A ZA202304536B ZA 202304536 B ZA202304536 B ZA 202304536B ZA 2023/04536 A ZA2023/04536 A ZA 2023/04536A ZA 202304536 A ZA202304536 A ZA 202304536A ZA 202304536 B ZA202304536 B ZA 202304536B
- Authority
- ZA
- South Africa
- Prior art keywords
- preventing
- fusion protein
- farbry
- attributed
- disease
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 201000001119 neuropathy Diseases 0.000 title abstract 2
- 230000007823 neuropathy Effects 0.000 title abstract 2
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152246 | 2020-11-13 | ||
| PCT/KR2021/016629 WO2022103220A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304536B true ZA202304536B (en) | 2024-09-25 |
Family
ID=81601490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04536A ZA202304536B (en) | 2020-11-13 | 2023-04-19 | Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230416714A1 (https=) |
| EP (1) | EP4245310A4 (https=) |
| JP (1) | JP2023549322A (https=) |
| KR (1) | KR20220065720A (https=) |
| CN (1) | CN116419759A (https=) |
| AU (1) | AU2021377712A1 (https=) |
| CA (1) | CA3196264A1 (https=) |
| CO (1) | CO2023006516A2 (https=) |
| IL (1) | IL302857A (https=) |
| MX (1) | MX2023005579A (https=) |
| WO (1) | WO2022103220A1 (https=) |
| ZA (1) | ZA202304536B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230134823A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| WO2018127920A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| AU2018295994B2 (en) * | 2017-07-07 | 2025-02-06 | Hanmi Pharm. Co., Ltd. | Novel therapeutic enzyme fusion protein and use thereof |
| CN111511910B (zh) * | 2017-12-22 | 2024-11-08 | 韩美药品株式会社 | 具有新颖结构的治疗酶融合蛋白及其用途 |
-
2021
- 2021-11-15 US US18/036,538 patent/US20230416714A1/en active Pending
- 2021-11-15 MX MX2023005579A patent/MX2023005579A/es unknown
- 2021-11-15 JP JP2023525997A patent/JP2023549322A/ja active Pending
- 2021-11-15 AU AU2021377712A patent/AU2021377712A1/en active Pending
- 2021-11-15 IL IL302857A patent/IL302857A/en unknown
- 2021-11-15 WO PCT/KR2021/016629 patent/WO2022103220A1/ko not_active Ceased
- 2021-11-15 KR KR1020210156862A patent/KR20220065720A/ko active Pending
- 2021-11-15 CN CN202180075085.8A patent/CN116419759A/zh active Pending
- 2021-11-15 EP EP21892387.8A patent/EP4245310A4/en active Pending
- 2021-11-15 CA CA3196264A patent/CA3196264A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04536A patent/ZA202304536B/en unknown
- 2023-05-17 CO CONC2023/0006516A patent/CO2023006516A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416714A1 (en) | 2023-12-28 |
| JP2023549322A (ja) | 2023-11-24 |
| AU2021377712A9 (en) | 2024-07-11 |
| EP4245310A4 (en) | 2024-10-30 |
| AU2021377712A1 (en) | 2023-06-01 |
| CA3196264A1 (en) | 2022-05-19 |
| IL302857A (en) | 2023-07-01 |
| KR20220065720A (ko) | 2022-05-20 |
| MX2023005579A (es) | 2023-05-29 |
| WO2022103220A1 (ko) | 2022-05-19 |
| CN116419759A (zh) | 2023-07-11 |
| CO2023006516A2 (es) | 2023-06-09 |
| EP4245310A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| MY209590A (en) | Anti-msr1 antibodies and methods of use thereof | |
| ATE314475T1 (de) | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität | |
| MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| CY1107248T1 (el) | Συντηγμενες πρωτεϊνες | |
| ATE198050T1 (de) | Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia | |
| ATE320811T1 (de) | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors | |
| MX2022004577A (es) | Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune. | |
| BR0207749A (pt) | Bactérias do ácido láctico como agentes para tratar e prevenir alergias | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| WO2021236981A3 (en) | Engineered parkin and uses thereof | |
| ZA202304536B (en) | Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease | |
| IL165858A (en) | Pharmaceutical preparation for treating human malignancies with arginine deprivation and uses thereof | |
| WO2021151043A3 (en) | Methods and compositions for treating and preventing viral infection | |
| MX2023004933A (es) | Proteinas de fusion de ace2 y usos de las mismas. | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| MX2022008953A (es) | Factores de transcripcion de proteina de dedos de zinc para reprimir la expresion de tau. | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| EP1969003A4 (en) | NEW NEUROTROPIC FACTOR PROTEIN AND APPLICATIONS THEREOF | |
| DK1042492T3 (da) | Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme | |
| ZA202106627B (en) | Treatment of headache using anti-cgrp antibodies | |
| MX2022012983A (es) | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. | |
| BR102020007149A8 (pt) | Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca | |
| MX2023005580A (es) | Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry. |